Home > Insider Trading > Filing (0000886163-21-000029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
886163	Ligand Pharmaceuticals Inc	LGND	Pharmaceutical Preparations (2834)	770160744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1237556	W Matthew Foehr	3911 Sorrento Valley Boulevard, Ste 110 San Diego CA 92121	President And Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-03	6,595	$0.00	167,198	No	4	A	Direct
Common Stock	Acquisiton	2021-02-04	1,000	$74.42	168,198	No	4	M	Direct
Common Stock	Acquisiton	2021-02-04	44,547	$21.92	212,745	No	4	M	Direct
Common Stock	Disposition	2021-02-04	44,547	$176.86	168,198	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-02-04	44,547	$0.00	44,547	$21.92
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-02-04	1,000	$0.00	1,000	$74.42
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2021-02-03	13,136	$0.00	13,136	$177.50

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,000	2023-02-15	No	4	M	Direct
63,210	2024-02-12	No	4	M	Direct
13,136	2031-02-03	No	4	A	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.52 to $180.89, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14.
Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021.